Sacubitril/Valsartan Tablet
Sacubitril/valsartan is an angiotensin receptor–neprilysin inhibitor (ARNI) that reduces harmful RAAS activation while boosting beneficial natriuretic peptides. In animals, it can help lower cardiac stress markers and support heart-failure management, particularly in conditions like mitral valve disease or DCM.
This compounded formulation combines sacubitril, a neprilysin inhibitor, with valsartan, an angiotensin receptor blocker (ARB) — two different drug classes. In compounding practice, clinicians may consider a combination like this for a multi-targeted approach. Your veterinarian determines whether it is appropriate based on your animal's diagnostic findings.
This description reflects the general pharmacology of the active ingredient's drug class; your veterinarian determines whether this approach is appropriate for your animal.
Prescription only. Use only under the direction of a licensed veterinarian. This information is not a substitute for veterinary diagnosis, prescribing or monitoring. Compounded drugs are not approved by the FDA for safety or effectiveness.
At a pharmacological level, sacubitril manages the degradation of natriuretic peptides while valsartan is used in the context of managing vascular resistance and fluid retention. Commonly observed effects include behavioral shifts such as lethargy or weakness and localized digestive changes. Because both ingredients influence blood pressure and renal function, your veterinarian will monitor for observational signs of kidney stress through regular blood work. Owners should monitor for significant changes in thirst or energy and contact their veterinarian promptly.
Yes. This combination requires a valid prescription from a licensed veterinarian before it can be dispensed. Mixlab ensures all legal and professional standards are met.
Yes. Mixlab specializes in compounding sacubitril and valsartan into customized flavored oral formats, such as flavored oral liquids, to suit the specific needs of your dog.
Veterinarians discuss this combination because it is used in the context of managing the heart's workload from two different pathways. This offers an approach to managing cardiac efficiency in dogs with advanced heart challenges.
Your veterinarian will recommend periodic blood work to monitor kidney values and blood pressure. This monitoring ensures the management approach remains safe for your pet's heart health.
Weakness can be an observational sign of low blood pressure. If you notice your pet appearing unusually unsteady or lethargic, contact your veterinarian immediately for a clinical review.
